Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML

The purpose of the study is to assess the safety, pharmacokinetics, and preliminary efficacy of AMX-883 monotherapy in participants with acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS) and in combination with anticancer agents in participants with AML.

Trial Details

NCT ID
NCT07723703
Phase
PHASE1
Sponsor
Amphista Therapeutics Ltd
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • AMX-883
  • Posaconazole
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597
  • Fairfax, Virginia, United States|38.84622,-77.30637
  • Manchester, Greater Manchester, United Kingdom|53.48095,-2.23743

Key Eligibility Criteria

  • Participants with relapsed or refractory AML who have failed all available standard therapies or relapsed or refractory high-risk MDS with BM blast…
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Adequate washout from prior therapies
  • Adequate kidney and liver function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →